Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization

Stefanie Derer; Christian Kellner; Thies Rösner; Katja Klausz; Pia Glorius; Thomas Valerius; Matthias Peipp

doi:10.1007/978-1-62703-992-5_33

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization

Stefanie Derer, Christian Kellner, Thies Rösner, Katja Klausz, Pia Glorius, Thomas Valerius, Matthias Peipp

Institute of Nutrition Medicine

University of Kiel

1 Citation (Scopus)

Abstract

Therapeutic antibodies used in the treatment of cancer patients are able to mediate diverse effector mechanisms. Dependent on tumor entity, localization, and tumor burden different effector mechanisms may contribute to the in vivo antitumor activity to a variable degree. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) have been suggested as being important for the in vivo activity of therapeutic antibodies like rituximab or trastuzumab. In recent years, several strategies have been pursued to further optimize the cytotoxic potential of monoclonal antibodies by modifying their Fc part (Fc engineering) with the ultimate goal to enhance antibody therapy. Since Fc engineering approaches are applicable to any Fc-containing molecule, strategies to enhance CDC or ADCC activity of full antibodies or scFv-Fc fusion proteins by altering the primary Fc sequence are described.

Original language	English
Title of host publication	Monoclonal Antibodies : Methods and Protocols
Number of pages	16
Publisher	Humana Press Inc.
Publication date	2014
Pages	525-540
ISBN (Print)	9781627039918
DOIs	https://doi.org/10.1007/978-1-62703-992-5_33
Publication status	Published - 2014

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-62703-992-5_33

Cite this

Derer, S., Kellner, C., Rösner, T., Klausz, K., Glorius, P., Valerius, T., & Peipp, M. (2014). Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization. In Monoclonal Antibodies: Methods and Protocols (pp. 525-540). (Methods in Molecular Biology; Vol. 1131). Humana Press Inc.. https://doi.org/10.1007/978-1-62703-992-5_33

@inbook{4f83dec0c35c498eb8da5eb1bcf4e694,

title = "Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization",

abstract = "Therapeutic antibodies used in the treatment of cancer patients are able to mediate diverse effector mechanisms. Dependent on tumor entity, localization, and tumor burden different effector mechanisms may contribute to the in vivo antitumor activity to a variable degree. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) have been suggested as being important for the in vivo activity of therapeutic antibodies like rituximab or trastuzumab. In recent years, several strategies have been pursued to further optimize the cytotoxic potential of monoclonal antibodies by modifying their Fc part (Fc engineering) with the ultimate goal to enhance antibody therapy. Since Fc engineering approaches are applicable to any Fc-containing molecule, strategies to enhance CDC or ADCC activity of full antibodies or scFv-Fc fusion proteins by altering the primary Fc sequence are described.",

author = "Stefanie Derer and Christian Kellner and Thies R{\"o}sner and Katja Klausz and Pia Glorius and Thomas Valerius and Matthias Peipp",

year = "2014",

doi = "10.1007/978-1-62703-992-5_33",

language = "English",

isbn = "9781627039918",

series = "Methods in Molecular Biology",

publisher = "Humana Press Inc.",

pages = "525--540",

booktitle = "Monoclonal Antibodies",

}

Derer, S, Kellner, C, Rösner, T, Klausz, K, Glorius, P, Valerius, T & Peipp, M 2014, Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization. in Monoclonal Antibodies: Methods and Protocols. Methods in Molecular Biology, vol. 1131, Humana Press Inc., pp. 525-540. https://doi.org/10.1007/978-1-62703-992-5_33

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization. / Derer, Stefanie; Kellner, Christian; Rösner, Thies et al.
Monoclonal Antibodies: Methods and Protocols. Humana Press Inc., 2014. p. 525-540 (Methods in Molecular Biology; Vol. 1131).

Research output: Chapters in Books/Reports/Conference Proceedings › Chapter › peer-review

TY - CHAP

T1 - Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization

AU - Derer, Stefanie

AU - Kellner, Christian

AU - Rösner, Thies

AU - Klausz, Katja

AU - Glorius, Pia

AU - Valerius, Thomas

AU - Peipp, Matthias

PY - 2014

Y1 - 2014

N2 - Therapeutic antibodies used in the treatment of cancer patients are able to mediate diverse effector mechanisms. Dependent on tumor entity, localization, and tumor burden different effector mechanisms may contribute to the in vivo antitumor activity to a variable degree. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) have been suggested as being important for the in vivo activity of therapeutic antibodies like rituximab or trastuzumab. In recent years, several strategies have been pursued to further optimize the cytotoxic potential of monoclonal antibodies by modifying their Fc part (Fc engineering) with the ultimate goal to enhance antibody therapy. Since Fc engineering approaches are applicable to any Fc-containing molecule, strategies to enhance CDC or ADCC activity of full antibodies or scFv-Fc fusion proteins by altering the primary Fc sequence are described.

AB - Therapeutic antibodies used in the treatment of cancer patients are able to mediate diverse effector mechanisms. Dependent on tumor entity, localization, and tumor burden different effector mechanisms may contribute to the in vivo antitumor activity to a variable degree. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) have been suggested as being important for the in vivo activity of therapeutic antibodies like rituximab or trastuzumab. In recent years, several strategies have been pursued to further optimize the cytotoxic potential of monoclonal antibodies by modifying their Fc part (Fc engineering) with the ultimate goal to enhance antibody therapy. Since Fc engineering approaches are applicable to any Fc-containing molecule, strategies to enhance CDC or ADCC activity of full antibodies or scFv-Fc fusion proteins by altering the primary Fc sequence are described.

UR - http://www.scopus.com/inward/record.url?scp=84934440590&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-992-5_33

DO - 10.1007/978-1-62703-992-5_33

M3 - Chapter

C2 - 24515488

AN - SCOPUS:84934440590

SN - 9781627039918

T3 - Methods in Molecular Biology

SP - 525

EP - 540

BT - Monoclonal Antibodies

PB - Humana Press Inc.

ER -

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this